An update in the diagnosis of coeliac disease

Marjorie M. Walker, Joseph A Murray

Research output: Contribution to journalReview article

58 Citations (Scopus)

Abstract

Coeliac disease is increasing in prevalence, which is currently estimated at one in 100 of the population and may occur de novo in adults. The diagnosis requires a joint clinicopathological approach; the recommended first-line test is serology with immunoglobulin A (IgA) tissue transglutaminase and IgA endomysial antibodies. These serological tests show high levels of sensitivity and specificity, but biopsy is the gold standard to confirm the diagnosis. It is important that both tests are performed before the introduction of a gluten-free diet. Although the classical histopathology changes of coeliac disease with partial or total villous atrophy are well recognized, the pathology classification of coeliac disease is changing, with recognition that coeliac disease may show minimal pathology (normal architecture and an intraepithelial lymphocyte count/100 enterocytes≥25). This entity is also described as lymphocytic duodenosis, and recommendation of follow-up serology testing is paramount in this condition. Follow-up of patients with coeliac disease is warranted, as normal serology does not predict mucosal recovery. Failure to heal predicts risk of progression to refractory coeliac disease and malignancies. Refractory coeliac disease occurs in 1-2% of patients and this diagnosis requires a combined clinical and histopathology approach with immunocytochemistry.

Original languageEnglish (US)
Pages (from-to)166-179
Number of pages14
JournalHistopathology
Volume59
Issue number2
DOIs
StatePublished - Aug 2011

Fingerprint

Celiac Disease
Serology
Immunoglobulin A
Pathology
Gluten-Free Diet
Lymphocyte Count
Serologic Tests
Atrophy
Joints
Immunohistochemistry
Biopsy
Sensitivity and Specificity
Antibodies
Population
Neoplasms

Keywords

  • Coeliac disease
  • HLA typing
  • Intraepithelial lymphocytes
  • Lymphocytic duodenosis
  • Refractory coeliac disease
  • Serology

ASJC Scopus subject areas

  • Histology
  • Pathology and Forensic Medicine

Cite this

An update in the diagnosis of coeliac disease. / Walker, Marjorie M.; Murray, Joseph A.

In: Histopathology, Vol. 59, No. 2, 08.2011, p. 166-179.

Research output: Contribution to journalReview article

Walker, Marjorie M. ; Murray, Joseph A. / An update in the diagnosis of coeliac disease. In: Histopathology. 2011 ; Vol. 59, No. 2. pp. 166-179.
@article{23bb00fe6adc43febadc763ebd14c61f,
title = "An update in the diagnosis of coeliac disease",
abstract = "Coeliac disease is increasing in prevalence, which is currently estimated at one in 100 of the population and may occur de novo in adults. The diagnosis requires a joint clinicopathological approach; the recommended first-line test is serology with immunoglobulin A (IgA) tissue transglutaminase and IgA endomysial antibodies. These serological tests show high levels of sensitivity and specificity, but biopsy is the gold standard to confirm the diagnosis. It is important that both tests are performed before the introduction of a gluten-free diet. Although the classical histopathology changes of coeliac disease with partial or total villous atrophy are well recognized, the pathology classification of coeliac disease is changing, with recognition that coeliac disease may show minimal pathology (normal architecture and an intraepithelial lymphocyte count/100 enterocytes≥25). This entity is also described as lymphocytic duodenosis, and recommendation of follow-up serology testing is paramount in this condition. Follow-up of patients with coeliac disease is warranted, as normal serology does not predict mucosal recovery. Failure to heal predicts risk of progression to refractory coeliac disease and malignancies. Refractory coeliac disease occurs in 1-2{\%} of patients and this diagnosis requires a combined clinical and histopathology approach with immunocytochemistry.",
keywords = "Coeliac disease, HLA typing, Intraepithelial lymphocytes, Lymphocytic duodenosis, Refractory coeliac disease, Serology",
author = "Walker, {Marjorie M.} and Murray, {Joseph A}",
year = "2011",
month = "8",
doi = "10.1111/j.1365-2559.2010.03680.x",
language = "English (US)",
volume = "59",
pages = "166--179",
journal = "Histopathology",
issn = "0309-0167",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - An update in the diagnosis of coeliac disease

AU - Walker, Marjorie M.

AU - Murray, Joseph A

PY - 2011/8

Y1 - 2011/8

N2 - Coeliac disease is increasing in prevalence, which is currently estimated at one in 100 of the population and may occur de novo in adults. The diagnosis requires a joint clinicopathological approach; the recommended first-line test is serology with immunoglobulin A (IgA) tissue transglutaminase and IgA endomysial antibodies. These serological tests show high levels of sensitivity and specificity, but biopsy is the gold standard to confirm the diagnosis. It is important that both tests are performed before the introduction of a gluten-free diet. Although the classical histopathology changes of coeliac disease with partial or total villous atrophy are well recognized, the pathology classification of coeliac disease is changing, with recognition that coeliac disease may show minimal pathology (normal architecture and an intraepithelial lymphocyte count/100 enterocytes≥25). This entity is also described as lymphocytic duodenosis, and recommendation of follow-up serology testing is paramount in this condition. Follow-up of patients with coeliac disease is warranted, as normal serology does not predict mucosal recovery. Failure to heal predicts risk of progression to refractory coeliac disease and malignancies. Refractory coeliac disease occurs in 1-2% of patients and this diagnosis requires a combined clinical and histopathology approach with immunocytochemistry.

AB - Coeliac disease is increasing in prevalence, which is currently estimated at one in 100 of the population and may occur de novo in adults. The diagnosis requires a joint clinicopathological approach; the recommended first-line test is serology with immunoglobulin A (IgA) tissue transglutaminase and IgA endomysial antibodies. These serological tests show high levels of sensitivity and specificity, but biopsy is the gold standard to confirm the diagnosis. It is important that both tests are performed before the introduction of a gluten-free diet. Although the classical histopathology changes of coeliac disease with partial or total villous atrophy are well recognized, the pathology classification of coeliac disease is changing, with recognition that coeliac disease may show minimal pathology (normal architecture and an intraepithelial lymphocyte count/100 enterocytes≥25). This entity is also described as lymphocytic duodenosis, and recommendation of follow-up serology testing is paramount in this condition. Follow-up of patients with coeliac disease is warranted, as normal serology does not predict mucosal recovery. Failure to heal predicts risk of progression to refractory coeliac disease and malignancies. Refractory coeliac disease occurs in 1-2% of patients and this diagnosis requires a combined clinical and histopathology approach with immunocytochemistry.

KW - Coeliac disease

KW - HLA typing

KW - Intraepithelial lymphocytes

KW - Lymphocytic duodenosis

KW - Refractory coeliac disease

KW - Serology

UR - http://www.scopus.com/inward/record.url?scp=80052199123&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052199123&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2559.2010.03680.x

DO - 10.1111/j.1365-2559.2010.03680.x

M3 - Review article

C2 - 21054494

AN - SCOPUS:80052199123

VL - 59

SP - 166

EP - 179

JO - Histopathology

JF - Histopathology

SN - 0309-0167

IS - 2

ER -